24 4月 がん治験における変化。よい薬へのより速いアクセスが可能に？
By ブレディー・デニス ＆ レニー・バーンステイン｜The Washington Post
The National Cancer Institute’s announcement Monday that it will soon begin a nationwide trial to test treatments based on the genetic mutations in patients’ tumors, rather than on where the tumors occur in the body, highlights a profound shift taking place in the development of cancer drugs.
Researchers increasingly are using DNA sequencing, which has become far faster and cheaper over time, to identify molecular abnormalities in cancers. That technology is allowing them to develop drugs they hope will prove more effective in specific sets of patients and to design clinical trials that get the most promising drugs to market more quickly…
